Praxis Precision Medicines (PRAX) Stock Skyrockets 180% on Game‑Changing Trial – Analysts See ‘Blockbuster’ Upside
Record Stock Surge on Phase 3 Breakthrough Praxis Precision Medicines shares skyrocketed on October 16, 2025, after the biotech reported game-changing Phase 3 trial results for its essential tremor drug. The stock closed that Thursday at $162.71, up over 183% in